Insider Selling: Enliven Therapeutics, Inc. (NASDAQ:ELVN) Insider Sells $14,513.58 in Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) insider Joseph P. Lyssikatos sold 527 shares of the business’s stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $27.54, for a total transaction of $14,513.58. Following the sale, the insider now directly owns 1,077,409 shares in the company, valued at $29,671,843.86. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Enliven Therapeutics Stock Up 7.9 %

Shares of NASDAQ ELVN opened at $27.53 on Friday. The company has a market capitalization of $1.29 billion, a PE ratio of -14.26 and a beta of 1.10. Enliven Therapeutics, Inc. has a twelve month low of $9.80 and a twelve month high of $27.67. The firm has a fifty day simple moving average of $23.21 and a 200 day simple moving average of $22.00.

Enliven Therapeutics (NASDAQ:ELVN) last posted its quarterly earnings data on Tuesday, August 13th. The company reported ($0.41) earnings per share for the quarter, topping the consensus estimate of ($0.58) by $0.17. As a group, equities analysts expect that Enliven Therapeutics, Inc. will post -1.98 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Enliven Therapeutics

Several institutional investors have recently added to or reduced their stakes in the business. First Turn Management LLC bought a new stake in shares of Enliven Therapeutics in the 2nd quarter valued at $9,657,000. Janus Henderson Group PLC increased its stake in Enliven Therapeutics by 74.8% in the first quarter. Janus Henderson Group PLC now owns 713,911 shares of the company’s stock valued at $12,604,000 after purchasing an additional 305,397 shares in the last quarter. Marshall Wace LLP acquired a new position in shares of Enliven Therapeutics during the second quarter valued at about $4,489,000. Baker BROS. Advisors LP bought a new position in shares of Enliven Therapeutics during the 1st quarter worth about $2,020,000. Finally, Nicholas Investment Partners LP acquired a new stake in shares of Enliven Therapeutics in the 2nd quarter valued at about $1,310,000. 95.08% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several analysts recently weighed in on the stock. HC Wainwright reissued a “buy” rating and issued a $37.00 price objective on shares of Enliven Therapeutics in a research note on Tuesday, October 1st. Robert W. Baird initiated coverage on Enliven Therapeutics in a research report on Tuesday, June 11th. They issued an “outperform” rating and a $32.00 price target on the stock. Finally, Baird R W upgraded Enliven Therapeutics to a “strong-buy” rating in a research report on Tuesday, June 11th.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.